Chronic kidney disease (CKD) has diverse causes and the outcomes can change with renal transplantation, which has the potential to increase quality of life and improve survival.
The primary objectives of these interventions are earlier detection and cancer prevention to increase quality of life and prolonged survival.
Non-invasive ventilation (NIV) can relieve dyspnoea, increase quality of life, and improve survival outcomes; particularly among ALS patients without severe bulbar symptoms [ 10- 13].
Advances in systemic disease control and overall survival may result in an increase in the number of patients who will eventually develop CNS metastases; therefore, better treatment options for CNS disease are needed to increase quality of life and prolong survival of these patients.
Despite promising results in animal tumor models in which anti-VEGF therapy translates into potent anti-tumor effects [ 1- 3], implementation of these therapies for a number of tumor types in the clinic has now learned that they, either or not in combination with chemotherapy, do increase quality of life or modestly prolong survival [ 4- 7], but lack curative effects [ 8, 9].
It is these drugs, either alone or in combination, that are designed to target strategic pathways to improve survival and increase quality of life in prostate cancer patients.
With the exception of testicular cancers, systemic therapy of GU cancers has a palliative character and aims to prolong survival and to increase quality of life.
To increase quality of life.
However, such variations are particularly worrisome for vulnerable older adults [ 2- 4] since for this population increased quality of care is associated with longer survival [ 5].
Certainly, NIPPV can account for improvements in clinical symptoms such as general well-being, appetite, exercise capability, headaches, ankle edema, and resurgence of acute failure, as well as decreasing hospitalization, increasing quality of life [ 78] and improving survival.
